Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LOTS trial (lurbinectedin): what clinicians have said so far
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
- NCT07153055 ↗
- Recruiting
- Misty Shields
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on LOTS (lurbinectedin plus osimertinib in transformed small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LOTS so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer
- Interventions
- Lurbinectedin; Osimertinib
- Arms
- Phase I Does De-Escalation · Experimental
- Phase II Dose Expansion · Experimental
- Enrollment
- 16 (estimated)
- Primary outcomes
- Grade 3 or dose-limiting toxicities
- Sponsor
- Misty Shields with Jazz Pharmaceuticals
- Start
- Jan 2027 (estimated)
- Primary completion
- Apr 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07153055 · updated Oct 15, 2026